

Induced Pluripotent Stem Cell-Derived Extracellular Vesicles Promote Wound Repair in a Diabetic Mouse Model via an Anti-Inflammatory Immunomodulatory Mechanism

Daniel Levy, Sanaz Nourmohammadi Abadchi, Niloufar Shababi, Mohsen Rouhani Ravari, Nicholas H. Pirolli, Cade Bergeron, Angel Obiorah, Farzad Mokhtari-Esbuie, Shayan Gheshlaghi, John M. Abraham, Ian M. Smith, Emily H. Powsner, Talia J. Solomon, John W. Harmon, and Steven M. Jay*

Extracellular vesicles (EVs) derived from mesenchymal stem/stromal cells (MSCs) have recently been explored in clinical trials for treatment of diseases with complex pathophysiologies. However, production of MSC EVs is currently hampered by donor-specific characteristics and limited ex vivo expansion capabilities before decreased potency, thus restricting their potential as a scalable and reproducible therapeutic. Induced pluripotent stem cells (iPSCs) represent a self-renewing source for obtaining differentiated iPSC-derived MSCs (iMSCs), circumventing both scalability and donor variability concerns for therapeutic EV production. Thus, it is initially sought to evaluate the therapeutic potential of iMSC EVs. Interestingly, while utilizing undifferentiated iPSC EVs as a control, it is found that their vascularization bioactivity is similar and their anti-inflammatory bioactivity is superior to donor-matched iMSC EVs in cell-based assays. To supplement this initial in vitro bioactivity screen, a diabetic wound healing mouse model where both the pro-vascularization and anti-inflammatory activity of these EVs would be beneficial is employed. In this in vivo model, iPSC EVs more effectively mediate inflammation resolution within the wound bed. Combined with the lack of additional differentiation steps required for iMSC generation, these results support the use of undifferentiated iPSCs as a source for therapeutic EV production with respect to both scalability and efficacy.

1. Introduction

While cell-based therapeutics featuring multipotent or progenitor cells have received significant interest in regenerative medicine and tissue repair applications,^[1,2] research has demonstrated that secreted factors such as cytokines, chemokines, and, especially, extracellular vesicles (EVs), play a substantial role in their therapeutic effects.^[3] EVs are cell-secreted, naturally-occurring nanoscale particles that function in intercellular communication via transfer of nucleic acids, lipids, and proteins to recipient cells.^[4] The biomolecular composition of EV cargos is determined by their parental cells, and EVs derived from cell sources with therapeutic potential such as multipotent or progenitor cells possess many of the same regenerative properties.^[3,5] Additionally, EVs are an attractive alternative to cell-based therapies due to a preferred safety profile as a result of their inability to replicate as well as their more predictable pharmacokinetic properties.^[6,7] However, scalable

D. Levy, N. H. Pirolli, C. Bergeron, A. Obiorah, I. M. Smith, E. H. Powsner, T. J. Solomon, S. M. Jay
Fischell Department of Bioengineering
University of Maryland
College Park, MD 20742, USA
E-mail: smjay@umd.edu

S. N. Abadchi, N. Shababi, M. R. Ravari, F. Mokhtari-Esbuie, S. Gheshlaghi, J. M. Abraham, J. W. Harmon
Department of Surgery
Johns Hopkins University School of Medicine
Baltimore, MD 21224, USA
S. M. Jay
Program in Molecular and Cell Biology
University of Maryland
College Park, MD 20742, USA

 The ORCID identification number(s) for the author(s) of this article can be found under <https://doi.org/10.1002/adhm.202300879>

© 2023 The Authors. Advanced Healthcare Materials published by Wiley-VCH GmbH. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

DOI: 10.1002/adhm.202300879

production of both cell- and EV-based therapies is currently a key limitation to their clinical translation.^[8,9]

Specifically, most cells used to produce therapeutic EVs have limited expansion capabilities.^[10,11] This includes mesenchymal stem/stromal cells (MSCs), which are among the most widely utilized cell sources for therapeutic EV production due to their multifactorial regenerative properties.^[10,12] Additionally, it has been demonstrated that increased ex vivo expansion of MSCs can affect their phenotype and therefore therapeutic efficacy; previously, it has also been observed that this decrease in efficacy translates to their secreted EVs.^[10,13] Currently, sourcing adult MSCs from various donors is a feasible workaround to the issues with limited expansion.^[14] However, donor variance in age, sex, and other genetic differences creates significant variability in the therapeutic potency of MSCs and their secreted EVs.^[15,16]

Toward addressing this limitation, researchers have attempted to develop a scalable source for therapeutic EVs by immortalizing MSCs.^[17–19] However, there are safety concerns associated with this strategy, as immortalization can make MSCs genetically similar to cancer cells.^[18,20] Another approach is to utilize MSCs differentiated from self-renewing induced pluripotent stem cells (iPSC-MSCs, or iMSCs),^[21] which can continually be produced from the same donor line, thus alleviating donor variability and scalability concerns, but at the cost of increased production time.^[22] Interestingly, researchers have begun to demonstrate the therapeutic utility of EVs from undifferentiated iPSCs, which require fewer processing steps to generate than iMSCs and thus are more favorable with respect to cost and reproducibility.^[22,23] For example, Adamiak et al. were able to utilize iPSC EVs to improve cardiac function in mice post-myocardial infarction, while Povero et al. demonstrated that iPSC EVs partially reverse murine liver fibrosis.^[24,25] While these initial works are promising and iPSC EV research is currently growing rapidly, studies have yet to fully benchmark the therapeutic efficacy of iPSC EVs against more established primary MSC or iMSC EVs; to date, only one other study compares MSC EVs against iPSC EVs in an in vitro aging model.^[23]

In this work, we demonstrate that iPSC EVs possess similar pro-angiogenic bioactivity to donor-matched iMSC EVs in vitro. Additionally, for the first time, we demonstrate that iPSC EVs possess anti-inflammatory properties comparable or superior to iMSC EVs. Further, in a diabetic murine wound healing model, we show that when compared to donor-matched iMSC EVs, iPSC EVs have superior therapeutic properties, functioning via modulation of the immune infiltrate. Our results provide a baseline for the use of iPSC EVs as a therapeutic modality upon which improvements to their bioactivity can be made via chemical priming, cargo loading, and other strategies. This study furthers the development of therapeutic EVs for use in tissue repair applications that require simultaneous modulation of complex, multifunctional regenerative pathways.

2. Results

2.1. EV Characterization and iPSC Pluripotency Confirmation

EVs were isolated via differential centrifugation coupled with tangential flow filtration (TFF) from the conditioned media of donor-

matched iPSCs and iMSCs. Non-donor matched BDMSC EVs were also isolated in the same fashion and utilized as a benchmark/additional control in further experiments. The size distribution and concentration of each EV group was assessed via nanoparticle tracking analysis (NTA). The size distributions for each EV isolate are within the expected size ranges of EV isolates (Figure 1A). Western blots were performed on EV and lysate samples from either iMSCs or iPSCs. In these blots, EV-associated surface markers ALIX and CD63 are present in both iPSC and iMSC-derived EVs, while the cellular protein marker Calnexin is absent from EV preparations (Figure 1B). Transmission electron microscopy (TEM) images indicate that both iPSC and iMSC EVs possess the correct spherical morphology consistent with EVs (Figure 1C). To confirm pluripotency, EV producing iPSCs were stained via immunocytochemistry (ICC) for SSEA4 and OCT4, and imaged using a Nikon fluorescence microscope (Figure 1D). Confirmation of iPSC pluripotency was then performed every approximately ten passages. Meanwhile, both SSEA4 and OCT4 expressions are absent from BDMSCs (acting as a control) (Figure S1A, Supporting Information).

Additionally, as we had observed possible particle contaminants from mTESR Plus complete media in EV isolation preparations despite being serum-free, the media was ultracentrifuged using the same protocol as employed for EV depletion to reduce possible large particle contaminants before culturing with iPSCs. The pluripotency of iPSCs cultured in this “depleted” mTESR Plus was confirmed via ICC staining for SSEA4 and OCT4 (Figure S1B, Supporting Information), and the depletion protocol largely removed large particle contaminants to near the lower limit of detection (Figure S1C, Supporting Information).

2.2. iPSC EVs Possess Similar Pro-Vascularization Potential to Donor-Matched iMSC EVs In Vitro

One goal of many MSC EV therapeutic approaches is to stimulate vascularization. To compare the pro-vascularization bioactivity of iPSC EVs against donor-matched iMSC EVs, a tube formation assay was performed with human umbilical vein endothelial cells (HUVECs) grown on growth-factor reduced Matrigel. At a dose of 5×10^9 particles per mL as assessed by NTA, donor-matched iMSC and iPSC EVs produced endothelial tube-like structures with similar amounts of branch points per field of view, which is significantly more compared to untreated HUVECs in endothelial basal media (Figure 2A). Additionally, a gap closure assay was performed on a confluent monolayer of HUVECs and again treatment with either iMSC or iPSC EVs yielded similar pro-vascularization potential over basal media control (Figure 2B).

To assess the ability of HUVECs to take up iPSC and iMSC EVs in vitro, EVs as well as a PBS mock control were exposed to fluorescent PKH67 dye and subjected to SEC to remove unbound dye before culturing with HUVECs for 24 h. HUVECs were then washed and imaged on a Nikon fluorescence microscope or fluorescence intensity was quantified via plate reader, with the data indicating similar uptake levels in HUVECs for both iPSC and iMSC EVs (Figure S2A, Supporting Information). Additionally,




Figure 1. Characterization of EV size, morphology, and protein markers of EVs and parental cells. A) NTA concentration and size distribution profiles of donor matched iPSC, iMSC, and non-donor matched BDMSC EVs. B) Western blot analysis of donor-matched iPSC and iMSC EV markers ALIX and CD63 as well as Calnexin, a negative marker. C) TEM images of iPSC and iMSC EVs post-isolation. D) Representative ICC images of SSEA4 and OCT4 expression to confirm pluripotency of EV-producing iPSCs.

EV-mediated HUVEC proliferation was assessed using a CCK8 assay. At a dose of 5×10^9 particles per mL, iPSC EVs induced proliferative bioactivity in HUVECs in vitro, whereas donor-matched iMSC EVs at the same dose did not (Figure S2B, Supporting Information).

2.3. iPSC EVs Exhibit Similar to Superior Anti-Inflammatory Bioactivity when Compared to Donor-Matched iMSC EVs

As MSC EVs have been extensively reported to possess anti-inflammatory properties, an in vitro lipopolysaccharide (LPS)-stimulated mouse macrophage model was used to benchmark the anti-inflammatory properties of iPSC EVs against donor-matched iMSC EVs.^[26] iPSC EV treatment significantly reduced the secretion of the pro-inflammatory cytokines/chemokines IL-6, TNF- α , CCL5, and IFN- β compared to controls (Figure 3A). iMSC EVs reduced IL-6, CCL5, and IFN- β levels compared to controls, but not TNF- α , and in each case the reduction was less than what was achieved by donor-matched iPSC EVs, with the disparities for TNF- α and CCL5 being statistically significant (Figure 3A). EV uptake by RAW264.7 cells was confirmed (Figure S3, Supporting Information), and validation of the dose-dependent nature of the anti-inflammatory effect of iPSC EVs was carried out for IL-6 (Figure 3B). Additionally, the ability of iPSC EVs to reduce inflammatory IL-6 levels did not change with increased passage (Figure 3C), supporting the concept that iPSCs can serve as sources for reproducible and

scalable biomanufacturing of therapeutic EVs, in contrast to donor-sourced primary MSCs.^[13] RT-quantitative polymerase chain reaction (qPCR) analysis on the cell lysate revealed that mRNA expression of IL-6, as well as TNF- α and iNOS, were also significantly reduced by either iPSC or iMSC EV treatment (Figure S4A, Supporting Information). Finally, a RAW264.7 NF- κ B reporter cell line was used to determine the ability of EVs to modulate inflammatory activation at the transcriptional activator level; both iPSC and iMSC EVs reduced NF- κ B activity compared to control as measured by alkaline phosphatase secretion (Figure S4B, Supporting Information).

Next, the potential of iPSC EVs to induce cellular changes related to inflammation resolution and repair was examined. As resolution typically occurs after an initial acute inflammation response, a “post-treat” cellular model was employed, where RAW264.7 macrophages were stimulated with 10 ng mL^{-1} LPS for 12 h before treatment with EVs at a dose of 5×10^9 particles per mL for 24 h.^[27] Via RT-qPCR analysis, expression of the anti-inflammatory cytokine IL-10 and the “M2” macrophage marker CD206 were both increased by treatment with iPSC EVs, while iMSC EVs had smaller effects (Figure 4A). Another key mechanism in inflammation resolution is the ability to dampen the release of reactive oxygen species (ROS), which have been established to be a partial driver of inflammatory responses in injury.^[28] Thus, EV-pre-treated RAW264.7s were stimulated with LPS (100 ng mL^{-1}) and H2DCFDA fluorescent probe was subsequently added to quantify relative ROS levels. Treatment with either iPSC EVs or iMSC EVs reduced fluorescent signals




Figure 2. iPSC EVs have similar pro-angiogenic potential to donor-matched iMSC EVs. A) After resuspension in EV treatments, HUVEC tube formation was quantified by the number of branch points per bright field image ($n = 3$). B) After inducing a scratch, HUVECs were treated with EVs in basal media and the percentage of gap closure was assessed using bright field images ($n = 4$). All values were expressed as mean $\pm$ standard deviation (** $p < 0.01$, *** $p < 0.001$). In all cases, data are representative of at least three independent experiments and EV isolations.

compared to LPS-stimulated RAW264.7s that received no pre-treatment (Figure 4B).

To confirm that iPSC EV preparations were effective in reducing inflammatory phenotypes in human cells in addition to mouse macrophages, a TNF- α stimulated HUVEC assay was used to assess expression of adhesion molecules utilized by leukocytes for extravasation into local sites of inflammation. iPSC EV treatment led to marginally decreased expression of VCAM-1 in this model (Figure 5A). Additionally, utilizing a stimulated human THP-1 assay, both iPSC EVs and iMSC EVs induced a robust decrease in TNF- α secretion as assessed by enzyme-linked immunosorbent assay (ELISA) (Figure 5B).

Our group previously reported on media contaminants affecting the outcomes of anti-inflammatory assays involving EVs.^[29] To verify that the reductions in pro-inflammatory cytokine secretion in this model were due to EVs and not media contaminants, the RAW264.7 pre-treat assay was performed using mTESR Plus that had undergone the EV isolation process. We observed that the mTESR Plus depletion protocol was effective at removing contaminants that may skew anti-inflammatory assay results; additionally, we saw that upon culture with iPSC EVs, the anti-inflammatory effect was restored (Figure S5A, Supporting Information). Another concern was the possibility that iPSC EV treatment was toxic to the RAW264.7s in this assay, leading to lower cytokine levels. However, using a CCK8 assay, we observed that

iPSC EV treatment actually increased cell viability and number (Figure S5B, Supporting Information).

2.4. iPSC EVs Reduce Gross Wound Size in a Db/Db Mouse Wound Healing Model

To compare the anti-inflammatory and pro-angiogenic properties of iPSC EVs and iMSC EVs in a more rigorous setting, a wound healing model in db/db mice was utilized (Figure 6A). Db/db mice were wounded via punch biopsy on their dorsum before EV injection around the wound 3 days after initial wounding. Wounds were traced every 3 days after EV injection to monitor wound size/closure over time. However, no significant increase in wound closure rate induced by either iPSC EVs or iMSC EVs was observed (Figure 6B). This was not surprising, as the wound healing model did not employ stenting, and thus wound closure was likely driven by the contraction of the surrounding skin tissue rather than the growth of new epithelial tissue.^[30]

For a more relevant assessment of healing in this model, epithelial tongue growth and wound area was examined histologically. Examination of images of H&E-stained tissues collected at 6 days post-wounding revealed significant amounts of necrotic tissue near the wound surface, underlying fibrotic tissue, and leukocyte infiltrate (Figure 7A), the latter of which




Figure 3. iPSC EVs possess superior anti-inflammatory properties compared to donor-matched iMSC EVs. A) RAW264.7 mouse macrophages were pre-treated with the indicated EV treatments before LPS stimulation. The cell supernatant was then collected and IL-6, TNF- α , CCL5, and IFN- β protein levels were quantified using ELISA ($n = 3$). B) RAW264.7 mouse macrophages were pre-treated with iPSC EVs at the indicated doses before LPS stimulation (10 ng mL^{-1}). Cell supernatants were collected and IL-6 levels were quantified using ELISA ($n = 3$). C) EVs isolated from iPSCs over multiple passages were used in the same LPS-stimulated RAW264.7 macrophage assay and IL-6 levels in the cell culture media was quantified via ELISA ($n = 3$). All values were expressed as mean $\pm$ standard deviation (* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$). In all cases, data are representative of at least three independent experiments and EV isolations.

can be instrumental to either resolution or persistence of chronic wounds.^[31] Additionally, re-epithelization of the wound bed occurred at an enhanced rate in iPSC EV-treated mice, as evidenced by an $\approx 85\%$ increase in new epithelial tongue length over the PBS control, while iMSC EV-treated wounds were not significantly different than vehicle-treated wounds (Figure 7A). When observing H&E-stained tissue slices from skin collected 18 days after initial wounding, blinded analysis indicated an $\approx 45\%$ reduction in total wound area in iPSC EV-treated mice compared to the PBS control, while iMSC EV treatment had no effect (Figure 7B). To confirm these findings, the lengths of wounds were measured by tracing the outer wound edges. Again, iMSC EV treatment was shown to have little effect in reducing wound length, while iPSC EV treatment induced a non-statistically significant $\approx 25\%$ decrease in wound length (Figure 7C). Further, a significant $\approx 50\%$ reduction in scar area was associated with iPSC EV treatment, with a non-significant

10% reduction achieved via iMSC EV treatment when compared to the vehicle control (Figure S6B, Supporting Information).

2.5. iPSC EVs Induce Anti-Inflammatory Macrophage Phenotypes In Vivo

To assess potential mechanisms of iPSC EV wound repair effects, anti-inflammatory activity was investigated following from the results of the prior in vitro experiments. At a timepoint reported to coincide with the inflammation resolution phase of wound healing (6 days after initial wounding),^[32] mice were sacrificed and a punch biopsy of the wound area was taken and processed for histological and immunohistochemical analyses. Immunohistochemistry (IHC) for F4/80, a general macrophage marker,^[31] indicated an $\approx 30\%$ increase in total macrophage infiltration in iPSC EV-treated wounds compared to vehicle-treated mice, with




Figure 4. iPSCs EVs resolve inflammation by transitioning macrophages to an “M2” phenotype and reduce ROS levels. A) In a “post-treat” regime, where RAW264.7s were stimulated with LPS, treated with EVs before lysis, anti-inflammatory macrophage markers/cytokine mRNA expression levels were quantified via RT-qPCR ($n = 3$). B) RAW264.7 mouse macrophages were pre-treated with EVs before LPS stimulation (100 ng mL^{-1}) and subsequent ROS quantification using a H2DCFDA fluorescent dye along with fluorescence quantification via plate reader ($n = 6$). All values were expressed as mean $\pm$ standard deviation (* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$). In all cases, data are representative of at least three independent experiments and EV isolations.




Figure 5. iPSC and iMSC EVs have anti-inflammatory effects in human cell models. A) HUVECs were pre-treated with EVs for 24 h at a dose of 5 E9 particles per mL before stimulation with 10 ng mL^{-1} TNF α for 16 h before lysing and quantification the endothelial adhesion marker, VCAM1 via RT-qPCR. B) We looked to confirm the anti-inflammatory effects of our EV samples in a human LPS-stimulated THP1 macrophage assay. The conditioned media of stimulated THP1s was collected and TNF- α levels were quantified via ELISA. All values were expressed as mean $\pm$ standard deviation (* $p < 0.05$, **** $p < 0.0001$). In all cases, data are representative of at least three independent experiments and EV isolations.

no significant increase over PBS control with iMSC EV treatment (Figure 8A).

To determine whether these infiltrating macrophages participated in inflammation persistence or resolution, IHC assessment of CD206, a “M2” macrophage marker indicative of

macrophages that actively aid the repair process,^[33] was performed. An $\approx 25\%$ increase in CD206 intensity in iPSC EV treated wounds over the PBS control was detected, while iMSC EVs did not induce a significant increase (Figure 8B). While macrophages are critical to the wound healing process, they





Figure 7. iPSC EVs improve wound tissue architecture during healing in a db/db mouse wound model. A) Representative images of H&E-stained wound beds 6 days post-wounding. Necrotic and apoptotic tissue are highlighted with red boxes. New epithelium was measured in length from the mature epithelium along the wound edge demarcated by black arrows ($n = 3-4$). B) Representative images of H&E-stained wound beds 18 days post-wounding. Total wound area was quantified by tracing the granulation tissue within the wound bed ($n = 3-4$). C) Representative images of H&E-stained wound beds 18 days after wounding. Wound length was quantified by tracing and measuring the outer wound edge ($n = 3-4$). All values were expressed as mean $\pm$ standard deviation ($*p < 0.05$).

was observed in iPSC EV-treated wounds (Figure 8C and Figure S7B, Supporting Information). Interestingly, the changes in anti-inflammatory markers/cytokines for iMSC EV treated wounds were all relatively marginal, indicating a muted immunomodulatory overall effect.

While it was expected that resolution of inflammation would largely be complete by 18 days post-wounding, F4/80 IHC and fluorescence imaging was performed at this time point for confirmation. As expected, macrophage infiltration was low and unchanged between the PBS control and both iPSC EV- and iMSC EV-treated wounds, indicating the inflammatory response was largely resolved by this time point (Figure S7C, Supporting Information). CD206 IHC was also performed at this time point, with results showing similar normalized intensity between PBS, iPSC EV-, and iMSC EV-treated wounds, with a slight $\approx 15\%$ increase in CD206 intensity in the iMSC EV group (Figure S7D, Supporting Information). This may indicate that iMSC EV treatment of wounds induces persistence of tissue repair-associated macrophages. Alternatively, when considering the CD206 data for wounds treated with iMSC EVs from the previous timepoint (Figure 8B,C), it could be that this tissue resolving effect was simply delayed compared to the iPSC EV and PBS groups.

2.6. iPSC EVs Marginally Affect Re-Vascularization in a Db/Db Mouse Wound Healing Model

As the wound should progress toward to the proliferative phase of repair by 18 days post-wounding, where re-vascularization plays a critical role in supplying nutrients to the repaired tissue, blood vessel formation was assessed at this timepoint via CD31 IHC.^[32] Non-statistically significant $\approx 35\%$ and $\approx 20\%$ increases in CD31+ vessel numbers were associated with iPSC EV and iMSC EV treatments, respectively (Figure 9A). Bulk RNA isolation from the wound tissue was again performed, this time to evaluate expression of pro-angiogenic markers VEGF, FGF1, FGF2, Angiopoietin2, PDGFb, and IGF1 via RT-qPCR. Overall, no changes in VEGF, PDGFb, FGF1, FGF2, or Angiopoietin2 expression were observed with either iPSC EV or iMSC EV treatment (Figure 9B). Interestingly, there was an $\approx 40\%$ increase in IGF1 expression in iPSC EV-treated wounds compared to the vehicle control (Figure 9B). Overall, this lack of evidence for substantial increases in vascularization is not entirely surprising, as we have previously demonstrated that unmodified MSC EVs had only marginal effects in increasing the number of blood vessels in the same wound healing model.^[36] However, it is important






Figure 9. iPSC EVs marginally affect re-vascularization during the proliferative phase of wound healing. A) Representative images of CD31 immunohistochemistry-stained tissue. Blood vessels were counted within a 1mm² field of view ($n = 4$). B) Pro-angiogenic growth factor expression was quantified via RT-qPCR from bulk mRNA isolated from wound tissue 18 days after wounding ($n = 4$). C) Representative images of H&E-stained tissue showing the lumen of blood vessels and blood cells within them. All values were expressed as mean $\pm$ standard deviation ($^*p < 0.05$).

to note that iPSC EVs were similarly ineffective at substantially improving angiogenesis in this wound model when compared to donor-matched iMSC EVs. While no substantial increase in revascularization was observed upon EV treatment, there was an apparent increase in functional blood vessels containing red blood cells from H&E-stained tissue slices (Figure 9C).

3. Discussion

Clinical trials and investment from industry into EV-based therapeutics continue to increase, driving the need to address the barriers that remain to their ultimate clinical translation including therapeutic potency and biomanufacturing.^[37,38] One key challenge is the issue of scalability. In particular, MSCs, a popular cell type for therapeutic EV production, have been widely reported to possess limited expansion capabilities *ex vivo*, thus capping the number of cells and EVs that can be produced from a singular MSC line.^[10] The effects of donor variability on MSC function are well reported, and this translates to their EVs as well, further limiting reproducible production of EVs with predictable therapeutic characteristics.^[16,39] Additionally, our group has previously demonstrated that EVs isolated from MSCs at higher passages begin to possess dampened functional bioactivity, imposing yet another limitation on the number of viable therapeutic EVs that can be obtained.^[13] Therefore, validation of scalable sources for therapeutic EV production is crucial to the continued development of this class of therapeutics.

The use of iPSCs for EV production is thus compelling due to their self-renewing capabilities.^[40] EVs from iPSCs have been

investigated in several applications to date, with promising results in models of cardiac injury, liver fibrosis, and cellular aging.^[23–25,41] The results of this study expand into the application space of wound repair, with surprising implications related to differentiation of iPSCs for EV production. Based on previous reports that iPSC EVs possess pro-angiogenic properties *in vitro*, we expected undifferentiated iPSC EVs to perform similarly to iMSC EVs in an *in vitro* angiogenic screen, which was born out in the results (Figure 2).^[24,41] However, due to the well-established anti-inflammatory properties of MSC EVs, we also expected iMSC EVs to outperform iPSC EVs in anti-inflammatory assays.^[42] Yet, we observed that iPSC EVs may have superior anti-inflammatory properties to EVs from donor-matched iMSCs in terms of both reducing pro-inflammatory phenotypes and inducing anti-inflammatory/inflammation resolving phenotypes (Figures 3–5). This finding is critical, as it further bolsters the rationale behind using EVs from undifferentiated iPSCs over iMSCs in addition to the production advantages inherent in avoiding additional differentiation steps. Furthermore, to date, the anti-inflammatory properties of iPSC EVs have yet to be thoroughly investigated. Additionally, we found that iPSC EVs retain bioactivity over many passages of the producer cells (Figure 4C), further emphasizing their enhanced utility compared to donor MSC EVs with respect to scalability.^[13]

Given that wound healing is a complex process that involves revascularization as well as macrophages playing an active role in both the promotion and resolution of inflammation, we hypothesized that this application may be appropriate for iPSC EVs.^[43] While there was no increase in wound closure overall, this may

be significantly attributed to limitations of the chosen model—wound closure in mouse wound healing models is affected not only by re-epithelization, as is the case in human wound healing, but also the contraction of surrounding skin tissue, which is the critical driver of wound closure in mouse models (Figure 6).^[30] Meanwhile, histological analysis demonstrated that iPSC EV treatment did increase the rate of new epithelium formation at earlier time points (Figure 7A), as well as smaller overall wound area and length at later time points (Figure 7B,C). Based on the slight increase in wound closure at the first time point associated with iPSC EV injection, the dosing scheme could be modified either by increasing the bolus dose or by employing repeated doses.

As there are distinct limitations with respect to wound closure rate in our model, we also assessed some of the cellular and molecular responses within the wound bed. We did not observe a decrease in pro-inflammatory mRNA expression levels upon EV treatment, which was surprising after observing such robust decreases in our *in vitro* model (Figure 3 and Figure S4, Supporting Information). It is possible that by harvesting tissues 3 days post-injection (6 days post-wounding), the peak wound inflammatory phase, which typically occurs 3–4 days post-wounding,^[32] was missed. This also applies with respect to peak neutrophil infiltration. However, we did observe an increase in macrophage infiltration within wounds 3 days after iPSC EV treatment as assessed by F4/80 IHC (Figure 8A). These infiltrating activated macrophages are likely “M2” macrophages, or inflammation resolution/tissue repair macrophages, as indicated by higher expression levels of CD163 and CD206 in iPSC EV-treated groups (Figure 8B,C).^[33] Due to these findings, we also looked at whether anti-inflammatory cytokines such as IL-10 and TGF β mRNA expression levels were increased, but saw only marginal, non-significant increases with iPSC EV treatment (Figure 8C and Figure S4B, Supporting Information). Interestingly, we did not observe many differences in inflammatory markers with iMSC EV treatment and actually observed increased iNOS expression and Ly6G intensity (Figure 8C and Figure S4A, Supporting Information), indicative of a discordance between the *in vitro* and *in vivo* results. These contradicting results may be due to the timing of *in vivo* sample acquisition as well as other factors.

As wounds begin to move into the proliferative phase of the healing process, nutrient supply to the repaired tissue is critical to inducing an environment hospitable to repair where promotion of angiogenesis is key.^[44] Thus, 15 days post-injection (18 days post-wounding), we assessed whether EV treatment improved revascularization of the tissue.^[32] Overall, no significant changes in promotion of angiogenesis in the wounds were observed associated with either iMSC or iPSC EV injection compared to vehicle control (Figure 9). These results are not surprising given that we previously reported that unmodified MSC EVs had little effect in increasing blood vessel number in the same model.^[36] Further, in addition to no significant changes in blood vessel density, there was little difference in pro-angiogenic mRNA expression within the wound bed between EV treatments and the vehicle control (Figure 9B). However, it was observed that IGF1 was increased in iPSC EV treated wounds by $\approx 40\%$ (Figure 9B). This is particularly interesting in a diabetic wound healing model specifically, given the role of IGF1 in insulin regulation.^[45] This result may also be supported by a recent study that profiled cargos within iPSC EVs, showing that many of these cargos are involved with

modulating metabolism and aging, which IGF1 is also involved in.^[46,47]

Given evidence that macrophage phenotypes are also related to cellular metabolism, it is possible that iPSC EVs may impart the observed “M2” transition through a similar pathway.^[48–50] However, further studies into the mechanism behind these anti-inflammatory phenomena are needed. Mechanistic studies are also needed to understand and rationally design enhanced iPSC EV-based therapeutics in the future.

However, between the lack of pro-vascularization and effect in wound closure rate in this db/db wound healing model, and despite iPSC EVs inherently possessing anti-inflammatory properties that can be utilized as a starting point for therapeutic development, strategies to enhance their overall therapeutic efficacy may be needed. Previously, we demonstrated that MSC EVs loaded with the long non-coding RNA, HOTAIR induced increased vascularization and improved wound closure rates in the same db/db wound healing model.^[36] The enhancement of MSC EV therapeutic efficacy has been widely described via chemical priming, cargo loading, and mechanical stimulation; however, as EVs from undifferentiated iPSCs have yet to be as rigorously evaluated, these enhancement strategies have yet to be employed for iPSC EVs.^[51–53]

Last, development of downstream processes to sustain scalable production, such as utilization of bioreactors or reducing the cost of media formulations, would aid in the translation of iPSC EVs to the clinic.^[8,54] Despite the bevy of possible studies that remain, the results here provide a starting point for the further development of iPSC EV-based therapeutics by demonstrating that iPSCs may be a superior alternative therapeutic EV source to iMSCs with respect to both therapeutic efficacy and scalability.

4. Experimental Section

Cell Culture: Human iPSCs (ACS-1026; American Type Culture Collection, Manassas, VA, USA) were cultured in mTESR Plus (100-0276; STEMCELL Technologies, Cambridge, MA, USA) complete medium on hESC-qualified Matrigel basement matrix (35 277; Corning; Corning, NY, USA) in either cell culture treated 6-well plates or T-75 tissue culture flasks; iPSCs arrived from the manufacturer at passage 22 and were not used for EV production for functional assays after more than 35 total passages. iPSCs were passaged before colonies began to touch and differentiate. Large particle-depleted mTESR Plus was generated by centrifugation of the complete medium at $100\,000 \times g$ for 16 h before collection of the supernatant.

Human iMSCs (ACS-7010; American Type Culture Collection, Manassas, VA, USA) donor-matched to the aforementioned iPSC line and non-donor matched human BDMSCs (PC-500-012; American Type Culture Collection, Manassas, VA, USA) were cultured in Dulbecco's modified Eagle's medium (DMEM) [–] 4.5 g L^{–1} glucose, L-glutamine and sodium pyruvate supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin and 1% non-essential amino acids in T-175 polystyrene tissue culture flasks. EV-depleted DMEM was generated via centrifugation of DMEM with supplements at $100\,000 \times g$ for 16 h before collecting the supernatant. iMSCs were passaged at $\approx 70\%$ confluency for maintenance; iMSCs arrived from the manufacturer at passage 6 and were not used for EV production for functional assays after more than ten total passages. BDMSCs were not used for EV production past four total passages.

HUVECs (C-12203; Promocell, Heidelberg, Germany) were cultured in T-75 tissue culture flasks coated with 0.1% gelatin using endothelial growth medium (C-C22121; PromoCell, Heidelberg, Germany). RAW264.7 mouse macrophages (T1B71; American Type Culture Collection, Manassas, VA, USA) were cultured in DMEM [–] 4.5 g L^{–1} glucose, L-glutamine

and sodium pyruvate supplemented with 1% penicillin-streptomycin and 5% FBS.

THP-1 human monocytes (TIB-202; American Type Culture Collection, Manassas, VA, USA) were cultured in T-175 tissue culture flasks in RPMI-1640 media supplemented with 10% heat-inactivated FBS and 1% penicillin-streptomycin inside a humidified 5% CO₂ 37 °C incubator. THP-1 cells were maintained at a concentration between 2×10^5 and 1×10^6 cells per mL by passaging by dilution without centrifugation, and cells between passages 8–12 were used for the inflammatory assay.

EV Isolation: BDMSCs or iMSCs were seeded into T-175 tissue culture flasks at $\approx 800\,000$ cells per flask and grown in EV-depleted medium. Conditioned medium was then collected over the following 3 days before being subjected to differential centrifugation steps at $1000 \times g$ for 10 min, $2000 \times g$ for 20 min, and $10\,000 \times g$ for 30 min. The supernatant from the final centrifugation step was then passed through a $0.2\,\mu\text{m}$ filter before subjection to TFF using a KrosFlo KR2i TFF system (Repligen; Boston, MA, USA). Using a protocol adapted from Heinemann et al., a 100 kDa MWCO MidiKros mPES membrane (D04-E100-05-N; Repligen, Boston, MA, USA) with six diafiltration steps and a transmembrane pressure of 5 PSI was used to concentrate samples to $\approx 10\text{--}15\,\text{mL}$.^[55] Samples were then further concentrated using a 100 kDa centrifugation spin concentrator (88 524; ThermoFisher Scientific; Waltham, MA, USA). Concentrated samples were then resuspended in $1 \times$ PBS and sterile filtered using a $0.2\,\mu\text{m}$ syringe filter. Samples were then stored at $-20\,^{\circ}\text{C}$ for no more than 2 weeks before use. Similarly, iPSCs were seeded into T-75s at an 8:10 dilution in colonies after passage from 6-well plates at 70% confluency. These iPSCs were grown in large particle-depleted mTESR Plus medium before media was collected and replaced daily for a total of 4 days. The collected conditioned medium was then subjected to the same differential centrifugation and TFF protocol as described above.

EV Characterization: EV size and number was quantified via NTA using a NanoSight LM10 (Malvern Panalytical Limited, Malvern, UK) with version 2.3 software. Each EV sample was monitored three times with a 30 s acquisition time. Samples were diluted to achieve 20–100 particles per frame to ensure an accurate measurement with camera levels and detection thresholds kept the same between EV samples.

TEM images were obtained by using a negative stain on EV samples. Briefly, EVs were incubated with electron microscopy-grade paraformaldehyde (157-400-100; Electron Microscopy Sciences, Hatfield, PA, USA) before floating a carbon film grid (CF-200-Cu-25; Electron Microscopy Sciences, Hatfield, PA, USA) on a droplet of the EV/PFA mixture. The grids were then washed by floating on a droplet of $1 \times$ PBS before being placed on a droplet of 1% glutaraldehyde. Next, the grid was washed using a droplet of MilliQ water before being floating on a droplet of uranyl acetate replacement stain (22 405; Electron Microscopy Sciences, Hatfield, PA, USA). Grids were then allowed to dry before storage and eventual imaging using a JEM 2100 LaB6 TEM (JEOL USA Incorporated; Peabody, MA, USA).

Protein concentration of EV samples was determined using a bicinchoninic acid (BCA) assay using the manufacturer's protocol (785-571; G-Biosciences, St. Louis, MO, USA). Equal amounts of protein of EV or lysate samples ($\approx 15\,\mu\text{g}$ per well) were then subjected to western blot analysis for ALIX (ab186429; Abcam, Cambridge, UK) at 1:1000, CD63 (25682-1-AP; ThermoFisher Scientific; Waltham, MA, USA) at 1:1000, and Calnexin (26795, C5C9; Cell Signaling Technology Incorporated, Danvers, MA, USA) at 1:1000 overnight at $4\,^{\circ}\text{C}$. The following day, goat anti-rabbit IRDye 800CW (925-32210; LI-COR Incorporated, Lincoln, NE, USA) was incubated with the membrane at a 1:10 000 dilution before imaging on an Odyssey CLx imager (LI-COR Incorporated, Lincoln, NE, USA).

iPSC Characterization: Pluripotency of iPSCs was confirmed over multiple passages and during EV production via immunofluorescence imaging. Cells were fixed using a 4% paraformaldehyde and 1% sucrose solution for 15 min before washing three times with $1 \times$ PBS. The cells were then permeabilized using a $6\,\mu\text{m}$ magnesium chloride, $20\,\text{mM}$ HEPES, $100\,\text{mM}$ sodium chloride, $300\,\text{mM}$ sucrose, and 0.5% Triton-X-100 solution for 5 min. After additional washing with $1 \times$ PBS, cells were stained with either Oct-4 (2890S, C52G3; Cell Signaling Technology Incorporated, Danvers, MA, USA) at a 1:500, or SSEA-4 (4755S, MC813; Cell Signaling Tech-

nology Incorporated, Danvers, MA, USA) at a 1:200 dilution and incubation overnight at $4\,^{\circ}\text{C}$. The following day, either a goat anti-rabbit (A32731; Thermo Scientific, Waltham, MA, USA) or goat anti-mouse (A32728; ThermoFisher Scientific, Waltham, MA, USA) secondary antibody at a concentration of $10\,\mu\text{g mL}^{-1}$ was incubated on the cells for 1 h in the dark. The cells were then stained with Hoechst 33 342 (62 248; ThermoFisher Scientific, Waltham, MA, USA) before imaging with a Nikon Ti2 microscope (Nikon; Minato City, Tokyo, Japan).

Angiogenic In Vitro Assays: To determine endothelial gap closure, passage 5 HUVECs were seeded onto 96-well plates coated with 0.1% gelatin at a seeding density of 15 000 cells per well in endothelial growth media. After $\approx 24\,\text{h}$, HUVECs had formed a confluent monolayer. The monolayer was then disrupted using a p200 pipette tip before washing with $1 \times$ PBS and serum-starving for 2 h with endothelial basal media supplemented with 0.1% FBS. Following serum-starving, medium was replaced with EV treatments at a concentration of 5E9 particles per mL suspended in endothelial basal media and imaged. 16 h later, the cells were imaged again, and the denuded area was quantified using ImageJ to determine gap closure percentage. Here, endothelial growth and basal media were used as positive and negative controls, respectively.

Tube formation assays were performed using passage 5 HUVECs. HUVECs were trypsinized and suspended in endothelial basal media supplemented with 0.1% FBS. Cells were then counted and 75 000 cells per group were aliquoted before pelleting at $300 \times g$. The pelleted cells were then resuspended in their respective treatments of EVs (5E9 particles per mL) in endothelial basal medium. The resuspended HUVECs were seeded onto 24-well plates coated with growth factor-reduced Matrigel (356 252; Corning, Corning, NY, USA). After 3–8 h, phase-contrast images of tube formation were taken, and the number of branch points was determined using ImageJ.

To observe endothelial proliferation, passage 5 HUVECs were seeded onto 0.1% gelatin-coated 96-well plates at a density of 3000 cells per well in endothelial growth media. The following day, cells were serum-starved with endothelial basal media supplemented with 0.1% FBS before replacing media with EV treatments (5E9 particles per mL) in basal media. 24 h later, media was replaced with endothelial basal media supplemented with 0.1% FBS and CCK-8 reagent. 2–4 h later, absorbance levels were quantified via plate reader.

Anti-Inflammatory In Vitro Assays: RAW264.7 mouse macrophages were seeded into 48-well plates in DMEM supplemented with 5% FBS and 1% penicillin-streptomycin at a seeding density of 75 000 cells per well. 24 h post-seeding, cells were pre-treated with either no treatment, $1\,\mu\text{g mL}^{-1}$ dexamethasone (D4902-25MG; Sigma-Aldrich, St. Louis, MO, USA), or EV treatments (5E9 particles per mL). The following day, media was replaced with $10\,\text{ng mL}^{-1}$ LPS (L4391-1MG; Sigma-Aldrich, St. Louis, MO, USA) diluted in DMEM supplemented with 5% FBS and 1% penicillin-streptomycin for 4 h. The conditioned media from treated RAW264.7s was then collected and stored at $-80\,^{\circ}\text{C}$ for assessment via ELISA. After collecting the conditioned media, cells were also washed with $1 \times$ PBS and lysed in QIAzol lysis reagent (79 306; QIAGEN, Hilden, Germany) for future RT-qPCR analysis.

The conditioned media from treated RAW264.7s was used to quantify levels of multiple secreted cytokines/chemokines using their respective ELISA kits including IL-6 (DY406; R&D Systems Incorporated, Minneapolis, MN, USA), TNF- α (DY410; R&D Systems Incorporated, Minneapolis, MN, USA), CCL5 (DY478; R&D Systems Incorporated, Minneapolis, MN, USA), and IFN- β (DY8234; R&D Systems Incorporated, Minneapolis, MN, USA). Using the collected RAW264.7 lysate, total RNA was isolated using a RNeasy mini kit (74 104; QIAGEN, Hilden, Germany) following the manufacturer's protocol. Complementary DNA (cDNA) was then generated from total RNA samples using M-MuLV reverse transcriptase (M0253L; New England Biosciences, Ipswich, MA, USA) according to the manufacturer's instructions. Following cDNA synthesis, quantitative polymerase chain reaction (qPCR) was performed using a QuantStudio 7 Flex qPCR system (4 485 701; ThermoFisher Scientific, Waltham, MA, USA) and PowerTrack SYBR Green Master Mix (A46109; Thermo Scientific, Waltham, MA, USA). Primer sequences used for qPCR are listed in Table S1, Supporting Information. The expression of mRNA transcripts was determined

using a comparative Ct method normalized to GAPDH expression and expressed as fold change of mRNA.

In “post treat” experiments looking at anti-inflammatory markers, RAW264.7 mouse macrophages were again seeded into 48-well plates in DMEM supplemented with 5% FBS and 1% penicillin-streptomycin at a seeding density of 75 000 cells per well. The following day, cells were treated with 10 ng mL⁻¹ LPS for 12 h before media was replaced with DMEM containing EV treatments (5E9 particles per mL) for 24 h. Cells were then washed with 1× PBS and lysed using Qiazol, and RNA isolation/cDNA synthesis was performed as described above for future qPCR analysis.

An NF- κ B RAW264.7 alkaline phosphatase-based reporter cell line, RAWblue (raw-sp; InvivoGen, San Diego, CA, USA) was utilized to observe the relative decrease in inflammatory signaling at the transcriptional activator level. RAWblue reporter cells were plated into a 48-well plate at a seeding density of 75 000 cells per well. The following day, cells were treated with EVs (5E9 particles per mL) or their respective controls and allowed to incubate for 24 h before stimulation with LPS (10 ng mL⁻¹) for 4 h. After LPS stimulation, per the manufacturer's protocol, 20 μ L of conditioned media was aliquoted and mixed with Quantibule solution (rep-qbs2; Invivogen, San Diego, CA, USA) and incubated in a 96-well plate for an additional 4 h before quantification via plate reader.

To determine relative ROS concentration, an ROS assay was performed. Here, RAW264.7s were seeded into a 96-well black wall plate at a density of 12 000 cells per well. Again, cells were pre-treated for 24 h with either EV (5E9 particles per mL) or control treatments before stimulation with LPS (100 ng mL⁻¹) for 4 h; here, treatment with Metformin (PHR1084; Sigma-Aldrich, St. Louis, MO, USA) was used as a positive control at a concentration of 100 nM. Post LPS stimulation, cells were washed with 1× PBS and incubated with a H2DCF2A probe (D399; ThermoFisher Scientific, Waltham, MA, USA) diluted in PBS at a concentration of 10 μ M for 30 min. After 30 min, the relative fluorescence intensity was determined via plate reader.

For the THP-1 inflammatory assay, THP-1 cells were plated in 48 well plates at 150 000 cells per well with 20 nM phorbol 12-myristate 13-acetate (PMA) (P8139-1MG; Sigma-Aldrich, St. Louis, MO, USA) supplemented in RPMI-1640 media +10% FBS and +1% penicillin-streptomycin to induce differentiation to monocyte-derived macrophages (dTHP-1), as previously described.^[56] After 24 h incubation with PMA, media was changed to fresh media and dTHP-1 cells were incubated for an additional 48 h to allow complete differentiation. Differentiation was verified by morphological changes and adherence to tissue culture plastic. Next dTHP-1 cells were pre-treated with 2.5 μ M dexamethasone as a positive control and EVs derived from iPSCs, iMSCs, and MSCs (5E9 particles per mL), and incubated for 24 h. Then, inflammation was stimulated using 250 ng mL⁻¹ LPS and 20 ng mL⁻¹ IFN- γ (300-02; PeproTech, Rocky Hill, NJ, USA). Conditioned media was collected 24 h later and stored at -80 °C until analysis of TNF- α levels via ELISA (DY210; R&D Systems, Minneapolis, MN, USA).

For the endothelial adhesion molecule assay, HUVECs were seeded into a 48-well plate at a density of 75 000 cells per well. Cells were then pre-treated for 24 h with either EVs (5E9 EVs per mL) or these controls, which includes Rapamycin (73 362; STEMCELL Technologies, Cambridge, MA, USA) at a concentration of 100 ng mL⁻¹ acting as a positive control. Next, media was replaced with endothelial growth media supplemented with 10 ng mL⁻¹ hTNF- α (300-01A; PeproTech, Rocky Hill, NJ, USA) for 16 h. Cells were then lysed using Qiazol and RNA isolation/cDNA synthesis was performed as described above.

EV Staining and Uptake: Either iPSC or iMSC-derived EVs were labeled with PKH67 (PKH67GL; Sigma-Aldrich, St. Louis, MO, USA). EVs were buffer exchanged with Diluent C using a 300 kDa MWCO Nanosep (OD300C35; Pall Corporation, New York, NY, USA) before resuspension of 200 μ g of EVs in 250 μ L of Diluent C. The resultant EV sample was then mixed at a 1:1 ratio with 4 μ M PKH67 dye in diluent C and allowed to incubate for 5 min with shaking. Subsequently, 1% BSA in diluent C was added to the EV/PKH67 solution at a 1:1:1 ratio and incubated for an additional 1 min. Dyed EV samples were then concentrated to 500 μ L using a 100 kDa centrifugation concentrator. Dyed EV samples were then centrifuged at 10 000 $\times$ g for 10 min to remove dyed protein aggregates. To en-

sure removal of contaminating dye aggregates, samples were run through size exclusion columns (ICO-35; Izon, Christchurch, New Zealand) following the manufacturer's protocol. Briefly, the first four 1 mL fractions after the void volume were collected, pooled, and concentrated with a 100 kDa MWCO centrifugation concentrator before resuspension in 1× PBS and subsequent sterile filtration using 0.2 μ m syringe filter. The concentration of dyed EVs was then quantified via NTA.

To assess uptake, HUVECs were seeded into endothelial growth media on 0.1% gelatin-coated 96-well black wall plates 24 h before treatment with 3E9 particles per mL for 24 h in endothelial growth media. Cells were then washed with 1× PBS three times and either imaged using a Nikon Ti2 microscope or quantified using a plate reader. Similarly, RAW264.7s were seeded into 96-well black wall plates and allowed to grow overnight before treatment with 3E9 particles per mL for 24 h. Again, cells were then washed with 1× PBS three times before either imaging or quantification via plate reader. To confirm that the authors were observing dyed EVs rather than uptake of dye aggregates, a mock dye solution was prepared using PBS with no EVs and subjected to the same staining and cell incubation process with both the HUVECs and RAW264.7s.

Animal Model: Twenty-four female Lepr^{db} mice (30–40 g) from Jackson Laboratory (Cat# 000967; Bar Harbor, ME), aged $\approx$ 6 weeks were utilized for wound healing experiments. The Johns Hopkins University Animal Care and Use Committee (ACUC) approved all murine procedures, all of which followed the Johns Hopkins University ACUC Protocol (MO20M08). Briefly, mice were anesthetized with 1.5% isoflurane (Baxter Healthcare Corporation, Deerfield, IL) and the entire dorsum was shaved. An 8 mm biopsy punch (Integra, Plainsboro, NJ) was then used to wound the mice on their dorsum. On day 0, Buprenorphine Sustained-Release (1 mg mL⁻¹ formulation) was locally administered subcutaneously at a dose of 0.5 mg kg⁻¹. Mice were divided into three groups, with eight mice per group: 1) vehicle control (PBS), 2) iPSC EVs, and 3) iMSC EVs. Group matching was accomplished based on the initial wound size and animal weights on day 0. Researchers were blinded during wounding and group matching, as well as throughout the entirety of the animal experimental process. 3 days post-wounding, a total of 7.2 $\times$ 10⁹ EVs (determined by NTA) were injected at four quadrants intradermally into mice in the treatment groups. In each injection, there were 1.8 $\times$ 10⁹ EVs in a total of 50 μ L of PBS. Mouse wound eschar was debrided with forceps on days 3, 6, 9, 15, and 18 to allow for clear visualization of the wound; at those time-points, wounds were photographed and traced with clear acetate paper. Tracings were then digitized, and the wound area was quantified using ImageJ. Wound closure rates were assessed over 18 days via planimetry as the percentage of the area of the wound versus the wound size on day 3 (injection of EVs). 6 days post-wounding four mice in each group were euthanized and wounds were biopsied using a 12 mm biopsy punch. The remaining four mice were monitored, with wounds traced until day 18 where they were also euthanized, and wounds were again biopsied.

Upon wound biopsy, the tissue was cut down the center and one half was placed in RNAlater (AM7020; ThermoFisher Scientific, Waltham, MA, USA) for future RNA isolation. The other tissue half was fixed in 10% formalin and stored overnight at 4 °C before briefly washing with 70% ethanol and placing in PBS before paraffin embedding and sectioning. A Leica RM2255 Motorized Rotary Microtome (Leica Biosystems; Wetzlar, Germany) was used to slice 5 μ m tissue sections before mounting. H&E staining of tissue sections was then performed after deparaffinization and rehydration. Briefly, slides were incubated with hematoxylin (75810-352; VWR, Radnor, PA, USA) for 10 min, rinsed with running DI water, followed by a 1 min incubation with differentiator solution (4% concentrated hydrochloric acid in 95% ethanol). Slides were then rinsed in DI water for $\approx$ 1 min before bluing in a 1% sodium bicarbonate solution for 1 min, washed for another $\approx$ 1 min in DI water, placed in 95% ethanol for 1 min, and incubated with eosin (75810-354; VWR, Radnor, PA, USA) for 1 min and subsequently dehydrated again. Permount (SP15-100; Fisher Scientific, Hampton, NH, USA) was then added before placing cover slips on slides at a 45° angle.

For histological analysis, H&E-stained slides were scanned and digitized. To quantify wound area, a blinded pathologist traced granulated tissue in both the dermis and new epidermis, and the area was measured

using ImageJ using a procedure adapted from Rhea et al.^[57] The scar area was quantified in a similar fashion by tracing the granulation tissue within the dermis and without the inclusion of the new epidermis.^[58] For the quantification of migrating epithelial tongues, the length of new epithelium which does not yet contain dermal papillae was measured from mature epithelium (containing dermal papillae) along the wound edge to the end of the new epithelium. Again, all histological analyses were performed by a blinded pathologist.

For IHC, mounted tissue sections were re-hydrated and antigen retrieval was performed by heating slides in a 10 mM sodium citrate buffer at 95 °C for 10–15 min. Slides were then cooled in a DI water bath, and tissue sections were circled with a liquid blocking pen. Slides were then washed with 1× TBS before blocking in a 1% bovine serum albumin (5 000 206; Bio-Rad, Hercules, CA, USA), and either 5% donkey (D9663-10ML; Sigma-Aldrich, St Louis, MO, USA) or goat serum (ab7481; Abcam, Cambridge, UK) solution. Slides were then incubated overnight at 4 °C with a 1:50 primary antibody solution of either CD206 (PA5-101657; Thermo Fisher Scientific, Waltham, MA, USA), F4/80 (MA5-16363; Thermo Fisher Scientific, Waltham, MA, USA), Ly6g (14-5931-85; Thermo Fisher Scientific, Waltham, MA, USA), or CD31 (ab28364; Abcam, Cambridge UK) in a humidified chamber. Slides were then washed with 1× TBS twice for 5 min each and incubated with either Alexa Fluor 647 donkey anti-rabbit secondary antibody (A31573, Thermo Fisher Scientific, Waltham, MA, USA) or Alexa Fluor 647 anti-rat secondary antibody (A-21247; Thermo Fisher Scientific, Waltham, MA, USA) at a 10 µg mL⁻¹ concentration for 1 h in a dark, humidified chamber. Slides were washed with 1× TBS twice again for 5 min each and Vectashield Mounting Media (H-1200; Vector Laboratories, Newark, CA, USA) was added before coverslipping. Cover slips were sealed with clear fingernail polish and fluorescence images were taken on a FV3000 laser scanning confocal microscope (Olympus, Tokyo, Japan) with the same laser settings between samples at either 10× or 20× magnification over multiple fields of view per tissue section. Using ImageJ, the number of cells was determined via DAPI staining, and fluorescence intensity for the wavelength corresponding with Alexa Fluor 647 was also determined. The fluorescence intensity/number of cells was then recorded and represented as fold change over the vehicle control group.

The other half of tissue samples that were later used for RT-qPCR were incubated in RNAlater overnight at 4 °C before placement in a –80 °C freezer before RNA isolation, which occurred within ≈5 days after tissue harvesting. Using a RNeasy kit from Qiagen (74 104; Qiagen, Hilden, Germany), tissue was then resuspended in Buffer RLT supplemented with β-mercaptoethanol (10 µL βME/1 mL RLT) at a ratio of 100 mg tissue to 1 mL RLT. Tissues were then homogenized with a Scilogex D160 homogenizer (Scilogex, Rocky Hill, CT, USA) before RNA isolation using the Qiagen RNeasy kit per the manufacturer's instructions. Reverse transcription was performed to generate cDNA in the same fashion as written above. Again, qPCR was performed in the same manner and primer sequences used for qPCR here are listed in Table S1, Supporting Information. The expression of mRNA transcripts was determined using a comparative Ct method normalized to β-Actin expression and expressed as fold change of mRNA.

Statistical Analysis: Data is presented as mean ± standard deviation. An ordinary one-way ANOVA was performed with either Dunnett's or Sidak's multiple comparisons test, or a 2-sample t-test was used to determine statistical significance. Statistical analyses were performed with Prism 9 (Graphpad Software). Statistical significance is shown as ns ($p > 0.05$), * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, or **** $p < 0.0001$ in figure captions.

Supporting Information

Supporting Information is available from the Wiley Online Library or from the author.

Acknowledgements

This work was supported by the National Institutes of Health (HL141611, NS110637, GM130923, HL141922, and HL159590 to S.M.J.; AI089621

to D.L.; and HL007698 to E.H.P.) and the National Science Foundation (1750542 to S.M.J.). D.L., T.J.S., and N.H.P. were supported by funds from the University of Maryland Foundation. J.W.H. was supported by the NIH (HL141611) and the Hendrix Burn/Wound Fund of Johns Hopkins University. The authors would like to acknowledge the University of Maryland School of Medicine's Pathology Histology Core—Baltimore, Maryland.

Conflict of Interest

The authors declare no conflict of interest.

Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Keywords

exosomes, induced pluripotent stem cells, induced pluripotent stem cell-mesenchymal stem/stromal cells, inflammation, wound healing

Received: March 19, 2023

Revised: June 7, 2023

Published online: June 27, 2023

- [1] A. Nagelkerke, M. Ojansivu, L. Van Der Koog, T. E. Whittaker, E. M. Cunnane, A. M. Silva, N. Dekker, M. M. Stevens, *Adv. Drug Delivery Rev.* **2021**, 175, 113775.
- [2] S. Keshtkar, N. Azarpira, M. H. Ghahremani, *Stem Cell Res. Ther.* **2018**, 9, 63.
- [3] S. Varderdidou-Minasian, M. J. Lorenowicz, *Theranostics* **2020**, 10, 5979.
- [4] D. E. Murphy, O. G. De Jong, M. Brouwer, M. J. Wood, G. Lavieu, R. M. Schiffelers, P. Vader, *Exp. Mol. Med.* **2019**, 51, 32.
- [5] M. P. Zaborowski, L. Balaj, X. O. Breakefield, C. P. Lai, *Bioscience* **2015**, 65, 783.
- [6] F. Villa, R. Quarto, R. Tasso, *Pharmaceutics* **2019**, 11, 557.
- [7] O. M. Elsharkasy, J. Z. Nordin, D. W. Hagey, O. G. De Jong, R. M. Schiffelers, S. E. Andaloussi, P. Vader, *Adv. Drug Delivery Rev.* **2020**, 159, 332.
- [8] C. Y. Ng, L. T. Kee, M. E. Al-Masawa, Q. H. Lee, T. Subramaniam, D. Kok, M. H. Ng, J. X. Law, *Int. J. Mol. Sci.* **2022**, 23, 7986.
- [9] S. Estes, K. Konstantinov, J. D. Young, *Curr. Opin. Biotechnol.* **2022**, 77, 102776.
- [10] Y.-H. K. Yang, C. R. Ogando, C. W. See, T.-Y. Chang, G. A. Barabino, *Stem Cell Res. Ther.* **2018**, 9, 131.
- [11] L. S. Wright, K. R. Prowse, K. Wallace, M. H. K. Linskens, C. N. Svendsen, *Exp. Cell Res.* **2006**, 312, 2107.
- [12] N. Heldring, I. Mäger, M. J. A. Wood, K. Le Blanc, S. E. L. Andaloussi, *Hum. Gene Ther.* **2015**, 26, 506.
- [13] D. B. Patel, K. M. Gray, Y. Santharam, T. N. Lamichhane, K. M. Stroka, S. M. Jay, *Bioeng. Transl. Med.* **2017**, 2, 170.
- [14] J. Cai, J. Wu, J. Wang, Y. Li, X. Hu, S. Luo, D. Xiang, *Cell Biosci.* **2020**, 10, 69.
- [15] D. G. Phinney, G. Kopen, W. Righter, S. Webster, N. Tremain, D. J. Prockop, *J. Cell. Biochem.* **1999**, 75, 424.
- [16] T. Wang, J. Zhang, J. Liao, F. Zhang, G. Zhou, *Stem Cells Transl. Med.* **2020**, 9, 1495.
- [17] T. S. Chen, F. Arslan, Y. Yin, S. S. Tan, R. C. Lai, A. B. H. Choo, J. Padmanabhan, C. N. Lee, D. P. De Kleijn, S. K. Lim, *J. Transl. Med.* **2011**, 9, 47.

- [18] T. T. Tan, R. C. Lai, J. Padmanabhan, W. K. Sim, A. B. H. Choo, S. K. Lim, *Pharmaceuticals* **2021**, *14*, 345.
- [19] A. Haghighitalab, M. M. Matin, A. Amin, S. Minaee, H. R. Bidkhori, T. R. Doeppner, A. R. Bahrami, *Sci. Rep.* **2021**, *11*, 7825.
- [20] K. W. Witwer, B. W. M. Van Balkom, S. Bruno, A. Choo, M. Dominici, M. Gimona, A. F. Hill, D. De Kleijn, M. Koh, R. C. Lai, S. A. Mitsialis, L. A. Ortiz, E. Rohde, T. Asada, W. S. Toh, D. J. Weiss, L. Zheng, B. Giebel, S. K. Lim, *J. Extracell. Vesicles* **2019**, *8*, 1609206.
- [21] J. Johnson, M. Shojaee, J. M. Crow, R. Khanabdali, *Front. Cell Dev. Biol.* **2021**, *9*, 705676.
- [22] K. Hynes, D. Menicanin, K. Mrozik, S. Gronthos, P. M. Bartold, *Stem Cells Dev.* **2014**, *23*, 1084.
- [23] S. Liu, V. Mahairaki, H. Bai, Z. Ding, J. Li, K. W. Witwer, L. Cheng, *Stem Cells* **2019**, *37*, 779.
- [24] M. Adamiak, G. Cheng, S. Bobis-Wozowicz, L. Zhao, S. Kedracka-Krok, A. Samanta, E. Karnas, Y.-T. Xuan, B. Skupien-Rabian, X. Chen, U. Jankowska, M. Girgis, M. Sekula, A. Davani, S. Lasota, R. J. Vincent, M. Sarna, K. L. Newell, O.-L. Wang, N. Dudley, Z. Madeja, B. Dawn, E. K. Zuba-Surma, *Circ. Res.* **2018**, *122*, 296.
- [25] D. Povero, E. M. Pinatel, A. Leszczynska, N. P. Goyal, T. Nishio, J. Kim, D. Kneiber, L. de Araujo Horcel, A. Eguchi, P. M. Ordonez, T. Kisseleva, A. E. Feldstein, *JCI Insight* **2019**, *4*, e125652.
- [26] P. D. Robbins, A. Dorronsoro, C. N. Booker, *J. Clin. Invest.* **2016**, *126*, 1173.
- [27] C. N. Serhan, S. D. Brain, C. D. Buckley, D. W. Gilroy, C. Haslett, L. A. J. O'Neill, M. Perretti, A. G. Rossi, J. L. Wallace, *FASEB J.* **2007**, *21*, 325.
- [28] M. Mittal, M. R. Siddiqui, K. Tran, S. P. Reddy, A. B. Malik, *Antioxid. Redox Signaling* **2014**, *20*, 1126.
- [29] S. M. Kronstadt, L. H. Van Heyningen, A. Aranda, S. M. Jay, *Cytotherapy* **2023**, *25*, 387.
- [30] H. D. Zomer, A. G. Trentin, *J. Dermatol. Sci.* **2018**, *90*, 3.
- [31] P. Krzyszczyk, R. Schloss, A. Palmer, F. Berthiaume, *Front. Physiol.* **2018**, *9*, 419.
- [32] N. X. Landén, D. Li, M. Stähle, *Cell. Mol. Life Sci.* **2016**, *73*, 3861.
- [33] T. J. Koh, L. A. Dipietro, *Expert Rev. Mol. Med.* **2011**, *13*, e23.
- [34] S. A. Eming, T. Krieg, J. M. Davidson, *J. Invest. Dermatol.* **2007**, *127*, 514.
- [35] P. Y. Lee, J.-X. Wang, E. Parisini, C. C. Dascher, P. A. Nigrovic, *J. Leukocyte Biol.* **2013**, *94*, 585.
- [36] L. J. Born, K.-H. Chang, P. Shoureshi, F. Lay, S. Bengali, A. T. W. Hsu, S. N. Abadchi, J. W. Harmon, S. M. Jay, *Adv. Healthcare Mater.* **2022**, *11*, 2002070.
- [37] I. K. Herrmann, M. J. A. Wood, G. Fuhrmann, *Nat. Nanotechnol.* **2021**, *16*, 748.
- [38] J. Rezaie, M. Fegghi, T. Etemadi, *Cell Commun. Signaling* **2022**, *20*, 145.
- [39] Y. P. Kang, N. P. Ward, G. M. DeNicola, *Exp. Mol. Med.* **2018**, *50*, 1.
- [40] C. M. Koch, K. Reck, K. Shao, Q. Lin, S. Joussen, P. Ziegler, G. Walenda, W. Drescher, B. Opalka, T. May, T. Brümmendorf, M. Zenke, T. Šarić, W. Wagner, *Genome Res.* **2013**, *23*, 248.
- [41] A. C. Andrade, M. Wolf, H.-M. Binder, F. G. Gomes, F. Manstein, P. Ebner-Peking, R. Poupardin, R. Zweigert, K. Schallmoser, D. Strunk, *Int. J. Mol. Sci.* **2021**, *22*, 3890.
- [42] C. Lo Sicco, D. Reverberi, C. Balbi, V. Ulivi, E. Principi, L. Pascucci, P. Becherini, M. C. Bosco, L. Varesio, C. Franzin, M. Pozzobon, R. Cancedda, R. Tasso, *Stem Cells Transl. Med.* **2017**, *6*, 1018.
- [43] T. Velnar, T. Bailey, V. Smrkolj, *J. Int. Med. Res.* **2009**, *37*, 1528.
- [44] M. G. Tonnesen, X. Feng, R. A. F. Clark, *J. Invest. Dermatol. Symp. Proc.* **2000**, *5*, 40.
- [45] D. J. Withers, M. White, *Endocrinology* **2000**, *141*, 1917.
- [46] Y. Bi, X. Qiao, Q. Liu, S. Song, K. Zhu, X. Qiu, X. Zhang, C. Jia, H. Wang, Z. Yang, Y. Zhang, G. Ji, *Stem Cell Res. Ther.* **2022**, *13*, 449.
- [47] S. Gupta, V. Krishnakumar, N. Soni, E. P. Rao, A. Banerjee, S. Mohanty, *Exp. Cell Res.* **2022**, *420*, 113354.
- [48] Y. Nakayama, K. Fujii, R. Yuki, Y. Oishi, M. S. Morioka, T. Isagawa, J. Matsuda, T. Oshima, T. Matsubara, J. Sugita, F. Kudo, A. Kaneda, Y. Endo, T. Nakayama, R. Nagai, I. Komuro, I. Manabe, *Proc. Natl. Acad. Sci. U. S. A.* **2020**, *117*, 14365.
- [49] Y. Liu, R. Xu, H. Gu, E. Zhang, J. Qu, W. Cao, X. Huang, H. Yan, J. He, Z. Cai, *Biomarker Res.* **2021**, *9*, 1.
- [50] A. Viola, F. Munari, R. Sánchez-Rodríguez, T. Scolaro, A. Castegna, *Front. Immunol.* **2019**, *10*, 1462.
- [51] S. M. Kronstadt, D. B. Patel, L. J. Born, D. Levy, M. J. Lerman, B. Mahadik, S. T. Mccloughlin, A. Fasuyi, L. Fowlkes, L. H. Van Heyningen, A. Aranda, S. N. Abadchi, K.-H. Chang, A. T. W. Hsu, S. Bengali, J. W. Harmon, J. P. Fisher, S. M. Jay, *Adv. Healthcare Mater.* **2023**, e2300584.
- [52] Y. Han, T. W. Jones, S. Dutta, Y. Zhu, X. Wang, S. P. Narayanan, S. C. Fagan, D. Zhang, *Processes* **2021**, *9*.
- [53] A. Cheng, D. Choi, M. Lora, D. Shum-Tim, J. Rak, I. Colmegna, *Stem Cell Res. Ther.* **2020**, *11*, 539.
- [54] C. Paganini, U. Capasso Palmiero, G. Pocsfalvi, N. Touzet, A. Bongiovanni, P. Arosio, *Biotechnol. J.* **2019**, *14*, 1800528.
- [55] M. L. Heinemann, M. Ilmer, L. P. Silva, D. H. Hawke, A. Recio, M. A. Vorontsova, E. Alt, J. Vykoukal, *J. Chromatogr. A* **2014**, *1371*, 125.
- [56] E. W. Baxter, A. E. Graham, N. A. Re, I. M. Carr, J. I. Robinson, S. L. Mackie, A. W. Morgan, *J. Immunol. Methods* **2020**, *478*, 112721.
- [57] L. Rhea, M. Dunnwald, *J. Visualized Exp.* **2020**, <https://doi.org/10.3791/61616>
- [58] H. Khorasani, Z. Zheng, C. Nguyen, J. Zara, X. Zhang, J. Wang, K. Ting, C. Soo, *Am. J. Pathol.* **2011**, *178*, 621.